Previous Close | 680.78 |
Open | 675.08 |
Bid | 777.25 |
Ask | 785.60 |
Strike | 175.00 |
Expire Date | 2025-01-17 |
Day's Range | 675.08 - 680.78 |
Contract Range | N/A |
Volume | |
Open Interest | 23 |
FDA Review Sparks Hope for Continued Access to Affordable Alternatives Amid Weight-Loss Drug Shortage
Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild weight-loss-drug market.